Understanding how ICBs manage Right to Choose activity

Guy Gross
Managing Partner, Regulum
Michelle Snook
Managing Partner, Regulum

Before starting on your Right to Choose journey as a healthcare provider, one of the most important things to understand is that patient demand and funded activity aren’t necessarily the same thing.

Integrated Care Boards (ICBs) are working with finite budgets, while trying to meet patient demand and uphold patient choice. To manage that, they use a range of mechanisms to plan activity, control expenditure and shape how referrals move through local pathways.

For providers like you, that means understanding not just whether patients can choose you, but how each ICB expects that activity to be managed and funded.

Get familiar with IAPs and AMPs

Two terms you’re likely to come across regularly are Indicative Activity Plans (IAPs) and Activity Management Plans (AMPs). They’re worth getting to grips with, as they can shape how much activity you’re able to deliver and how the commissioner manages any changes.

An Indicative Activity Plan sets out the level and value of activity an ICB expects a provider to deliver over a given period.

An Activity Management Plan is a more active control used where actual or forecast activity moves away from that plan. It might set out how activity, waiting lists and financial consequences will be managed.

We’d really encourage providers not to treat an IAP as just another administrative spreadsheet; it’s a crucial document that can affect how much activity an ICB expects to fund, how that activity is phased and how existing patients are accounted for.

When you receive one, check the following:

  • What period it covers
  • Which patients and pathway stages are included
  • The tariffs being used – is it a direct NHS contract, or NHS Non-Contract Activity (NCA)?
  • How urgent, complex or ongoing cases are treated
  • What reporting and escalation process applies

You should also understand what happens if you disagree with the proposal. Depending on the process, there could be opportunities to respond, raise an Activity Query Notice or enter a review before further controls are applied.

And remember that IAPs and AMPs aren’t the only levers commissioners can use. Prior approval, local eligibility criteria and other commissioned arrangements can also affect how activity progresses.

How do referrals reach Right to Choose providers?

The referral route can affect how quickly patients reach you and how much visibility you have over future demand. Some ICBs use a Single Point of Access (SPoA), where referrals pass through a central coordination or triage stage before reaching the provider. That service may check eligibility, assess urgency, request missing information or coordinate onward referral.

This has its pros and cons. It improves the quality and consistency of referral information and can identify incomplete or inappropriate referrals earlier. But it can also add another stage between patient choice and your service, affecting referral volumes, speed and eligibility decisions.

You also need to understand whether the pathway is direct or indirect. In some services, patients can be referred relatively directly to their chosen provider. In others, the referral might need to pass through general practice or another local interface first.

For any region you’re targeting, map the whole referral journey before you make assumptions about demand. Find out who can refer, where referrals go first, which local interfaces sit between the referrer and your organisation and where patient choice is recorded.

What does the NHS tariff include?

The headline tariff will only tell you part of what you need to know. You also need to understand exactly what the commissioner expects you to deliver for that price:

  • Does it include assessment alone or the full pathway?
  • How are more complex patients treated?
  • Are titration, prescribing, medication costs, follow-up or annual review included?
  • What reporting and assurance work is expected alongside delivery?

Those details can materially change the economics of the service. We’ve worked with Right to Choose providers where tariff reductions meant revisiting workforce costs and pathway design while the underlying costs of governance, prescribing infrastructure, administration and quality assurance remained.

Data requirements add another layer too. Providers may need to submit national datasets such as the Mental Health Services Data Set (MHSDS), as well as additional commissioner-specific reporting.

Our advice is to build some flexibility into your model. Today’s tariff, reporting requirement or pathway definition shouldn’t automatically be treated as permanent.

New providers could start at a disadvantage

Established providers are more likely to have historic referral data, known activity levels, existing commissioner relationships and mature reporting systems. That gives an ICB more information to work with when setting activity plans.

A new entrant, on the other hand, might be clinically ready to deliver the service but have no previous activity to base those plans on. That can create a difficult cycle: a smaller Indicative Activity Plan means fewer patients moving through the service, which then gives the provider less history to point to when future plans are set.

We sometimes describe it like dividing up a cake: established providers with high volumes may receive a larger share of planned activity, leaving newer entrants with a much smaller starting point.

That doesn’t make entry impossible. It does mean you should be cautious about building a large cost base on the assumption that high patient demand will immediately translate into high funded volumes.

So if you’re entering the market without historic activity, build your cost base around the level of activity you can realistically evidence and expect to be funded for. Start collecting your referral, delivery and outcome data nice and early too: the clearer your evidence base becomes, the more useful it’ll be when future activity plans are discussed.

Give commissioners evidence they can work with

You can’t remove the financial pressures facing ICBs, but you can control how prepared you are for conversations about activity. In a nutshell, good data matters, and you should be able to show commissioners exactly what is happening across your pathway:

  • How many referrals you’ve received
  • How many patients are waiting or booked
  • Where patients sit within the pathway
  • The complexity and cost of the caseload
  • What activity you expect to deliver next

Keep the different stages of the pathway visible too. Assessment, titration, prescribing and review can create very different costs. If an activity plan misses ongoing patients, medication costs or a more complex case mix, raise that clearly and in writing.

Our experience has shown commissioner conversations are much more productive when you’re able to bring actual referral data, existing patient commitments and realistic delivery projections, rather than relying only on general arguments about demand or Right to Choose.

The aim is to understand the commissioner’s constraints, show clearly what your service is dealing with and agree what can realistically be delivered.

How much do Right to Choose requirements vary between ICBs?

Across the country we see common themes, such as tighter financial control, stronger activity planning, more data requirements, greater invoice scrutiny and more attention to full-pathway delivery.

And although the underlying pressures are similar, the detail can still vary considerably between ICBs.

Different areas may take different approaches to tariffs, eligibility, prioritisation, face-to-face requirements, reporting, accreditation, shared care or referral interfaces.

Even activity above an IAP may be handled differently. One commissioner may allow some activity with retrospective reporting, while another may expect prior approval.

So while we wouldn’t reduce the whole system to a simple ‘postcode lottery’, providers should expect meaningful regional variation.

That should influence where you expand. Before entering a new area, look at the ICB’s accreditation process, use of SPoAs or prior approval, likely activity planning, tariff, pathway requirements, shared-care expectations, reporting obligations and onboarding arrangements.

An area with high demand can still be commercially difficult if funded activity is limited or local requirements add significant cost. The strongest opportunities are where patient need, your clinical capability, local commissioning requirements and the economics of delivery all align.

Patient choice doesn’t mean unlimited activity

If there’s one thing we’d want Right to Choose providers to understand, it’s that patient choice and unlimited provider activity aren’t treated as the same.

ICBs are trying to reconcile patient rights and clinical demand with finite financial envelopes. That’s why IAPs, AMPs, prior approval, triage, reporting requirements and invoice validation are all so important.

A referral may be valid under Right to Choose, but you still need to understand how the commissioner expects the resulting activity to be managed and funded.

That local funding and activity-management position should be part of your planning from the outset, particularly if you’re building workforce or infrastructure around anticipated referral volumes.

Dr Guy Gross is an executive leader, qualified doctor,and Managing Partner at Regulum, an advisory firm specialising in healthtech, digital care pathways, and NHS market strategy. Bringing extensive cross-sectorhealthcare expertise across operations and strategy, he has advisedcommissioners, health systems, Governments and high-growth providers onintegrated care models and clinical access.

Notably, as Interim Group COO at Psychiatry UK, Dr Grossembedded robust scalable operations to navigate surging patient demand acrossneurodiversity services. Drawing on senior roles across health consultancies,Teladoc Health, and LaingBuisson, he provides deep strategic insight into Rightto Choose pathways, patient empowerment, and independent sector delivery withinthe NHS.

‍

Michelle Snook is a healthcare operations, commissioning and transformation specialist with experience across NHS and independent sector services. She has led the development, procurement, commissioning and delivery of neurodevelopmental and substance misuse pathways, with expertise spanning ADHD and autism services, contract management, governance and operational delivery.

Michelle is a Managing Partner at Regulum, where she advises on healthcare commissioning, provider strategy, pathway design and NHS market engagement. Having worked as both a commissioner and provider, she brings a practical understanding of how to build clinically robust, financially sustainable services that can navigate complex NHS commissioning requirements, including Right to Choose.

Featured

No items found.
Ready to join thousands that already trust Semble?
4.5 Capterra
4.3 Google